

Golimumab Formulation

Version 1.23 Revision Date: 23.02.2023 SDS Number: 26450-00024 Date of last issue: 13.02.2023
Date of first issue: 29.10.2014

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Golimumab Formulation

Manufacturer or supplier's details

Company : MSD
Address : 50 Tuas West Drive
Singapore - Singapore 638408
Telephone : +1-908-740-4000
Emergency telephone number : 65 6697 2111 (24/7/365)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use


Recommended use : Pharmaceutical
Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS Classification

Respiratory sensitisation : Category 1

GHS label elements

Hazard pictograms : 

Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary statements : **Prevention:**
P261 Avoid breathing mist or vapours.
P284 Wear respiratory protection.
Response:
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.
Disposal:
P501 Dispose of contents/ container to an approved waste

Golimumab Formulation

Version 1.23 Revision Date: 23.02.2023 SDS Number: 26450-00024 Date of last issue: 13.02.2023
 Date of first issue: 29.10.2014

disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Golimumab	476181-74-5	>= 10 -< 20

4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
 If not breathing, give artificial respiration.
 If breathing is difficult, give oxygen.
 Get medical attention.
- In case of skin contact : Wash with water and soap as a precaution.
 Get medical attention if symptoms occur.
- In case of eye contact : Flush eyes with water as a precaution.
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
 Get medical attention if symptoms occur.
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).
 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray
 Alcohol-resistant foam
 Carbon dioxide (CO₂)
 Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
 Sulphur oxides

Golimumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.02.2023
1.23	23.02.2023	26450-00024	Date of first issue: 29.10.2014

- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
-

6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-

7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Avoid breathing mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
Take care to prevent spills, waste and minimize release to the

Golimumab Formulation

Version 1.23 Revision Date: 23.02.2023 SDS Number: 26450-00024 Date of last issue: 13.02.2023
 Date of first issue: 29.10.2014

environment.
 Conditions for safe storage : Keep in properly labelled containers.
 Keep tightly closed.
 Store in accordance with the particular national regulations.
 Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Golimumab	476181-74-5	TWA	70 µg/m ³ (OEB 3)	Internal

Engineering measures : Ensure adequate ventilation, especially in confined areas.
 Minimize workplace exposure concentrations.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:
 Safety glasses

Skin and body protection : Skin should be washed after contact.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

When using do not eat, drink or smoke.
 Wash contaminated clothing before re-use.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Colour : opalescent

Odour : No data available

Odour Threshold : No data available

Golimumab Formulation

Version 1.23 Revision Date: 23.02.2023 SDS Number: 26450-00024 Date of last issue: 13.02.2023
Date of first issue: 29.10.2014

pH	:	5.5
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Solubility(ies) Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac-	:	Can react with strong oxidizing agents.

Golimumab Formulation

Version 1.23 Revision Date: 23.02.2023 SDS Number: 26450-00024 Date of last issue: 13.02.2023
Date of first issue: 29.10.2014

tions
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:**Golimumab:**

Exposure routes : Inhalation
Assessment : May cause sensitisation by inhalation.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

Components:**Golimumab:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Mouse, male
Application Route: Intravenous injection
Fertility: NOAEL Parent: 40 mg/kg body weight

Test Type: Fertility/early embryonic development
Species: Mouse, female
Application Route: Intravenous injection
Fertility: NOAEL Parent: 40 mg/kg body weight

Golimumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.02.2023
1.23	23.02.2023	26450-00024	Date of first issue: 29.10.2014

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Monkey
 Teratogenicity: NOAEL: 100 mg/kg body weight
 Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight

Test Type: Development
 Species: Monkey
 Developmental Toxicity: NOAEL F1: 50 mg/kg body weight

Test Type: Embryo-foetal development
 Species: Mouse
 Application Route: Intravenous injection
 Teratogenicity: NOAEL: 40 mg/kg body weight
 Embryo-foetal toxicity: NOAEL: 40 mg/kg body weight
 Result: negative, No effects on foetal development

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Golimumab:

Species : Monkey
 NOAEL : 50 mg/kg
 Application Route : Intravenous
 Exposure time : 6 Months
 Number of exposures : Intermittent

Species : Monkey
 NOAEL : 25 mg/kg
 Application Route : Subcutaneous
 Exposure time : 6 Months

Species : Mouse
 NOAEL : 40 mg/kg
 Application Route : Intravenous

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Golimumab:

Inhalation : Symptoms: mild infections, upper respiratory tract infection, viral infections, bronchitis, sinusitis, fungal infections

Golimumab Formulation

Version 1.23 Revision Date: 23.02.2023 SDS Number: 26450-00024 Date of last issue: 13.02.2023
Date of first issue: 29.10.2014

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Golimumab:****Ecotoxicology Assessment**

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo) : Not applicable

Golimumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.02.2023
1.23	23.02.2023	26450-00024	Date of first issue: 29.10.2014

aircraft)
 Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
 Proper shipping name : Not applicable
 Class : Not applicable
 Subsidiary risk : Not applicable
 Packing group : Not applicable
 Labels : Not applicable
 EmS Code : Not applicable
 Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable
 Environmental Protection and Management (Hazardous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) : Not applicable
 Regulations

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 23.02.2023

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Golimumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.02.2023
1.23	23.02.2023	26450-00024	Date of first issue: 29.10.2014

Full text of other abbreviations

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN